Intervention

Interferon beta-1b (Betaseron, BAY86-5046)

ClinicalTrials.gov intervention label

Clinical trials19

Recruiting0

Common conditions9

Lead sponsors shown1

Clinical trials

19 shown

Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient SatisfactionNCT02652091 · 2016-02-05

Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)NCT01706055 · 2012-09-01

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple SclerosisNCT01491100 · 2012-04-30

China Betaferon Adherence, Coping and Nurse Support StudyNCT01436838 · 2012-03-01

Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years PeriodNCT01076595 · 2010-05-01

Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple SclerosisNCT00963833 · 2009-12-17

Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)NCT00902135 · 2009-05-01

Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1bNCT03408093 · 2009-02-03

Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple SclerosisNCT01184833 · 2008-09-01

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon TreatmentNCT00787657 · 2008-06-01

Betaferon® Regulatory Post-Marketing SurveillanceNCT01414816 · 2008-04-01

BENEFIT Extension StudyNCT00544037 · 2007-09-01

Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectorsNCT01235455 · 2007-08-01

BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New DoseNCT00459667 · 2007-05-01

Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple SclerosisNCT00370071 · 2006-11-01

Physical Activity and Fatigue in Early Multiple Sclerosis (MS)NCT00882453 · 2006-08-01

Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple SclerosisNCT00206635 · 2005-01-01

BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus ProgramNCT01233245 · 2004-04-01

BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up StudyNCT00185211 · 2002-08-01

Common conditions

Multiple Sclerosis12 Multiple Sclerosis, Relapsing-Remitting2 Relapsing Remitting Multiple Sclerosis (RRMS)2 Clinically Isolated System1 Multiple Sclerosis, Chronic Progressive1 Relapsing Remitting MS (RRMS)1 Relapsing-Remitting Multiple Sclerosis1 Secondary Progressive MS (SPMS)1 Secondary Progressive Multiple Sclerosis (SPMS)1

Leading sponsors

Trial status mix

COMPLETED19

Phase mix

PHASE33

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.